Efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review and meta-analysis

Efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review and meta-analysis

IntroductionThe combination of PD-1/PD-L1 inhibitor with CTLA-4 inhibitor for advanced non-small cell lung cancer(NSCLC) is presently a significant area of research, however its clinical application remains contentious. This meta-analysis aimed to assess the efficacy and safety of first-line PD-1/PD...

Full description

Saved in:
Bibliographic Details
Main Authors: Huimin Zhao, Shanshan Huang, Jianyu Wu, Yanlan Lu, Yue Zou, Haijian Zeng, Chunlan Li, Jin Wang, Xiaochen Zhang, Siliang Duan, Weiming Liang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Immunology
Subjects:
PD-1 inhibitor
programmed cell death protein 1 inhibitor
CTLA-4 inhibitor
non-small cell lung cancer
overall survival
objective response rate
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1515027/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items